Daniel Pink
Daniel Pink
Department of Hematology and Oncology, HELIOS Klinikum Bad Saarow
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced …
SE Al-Batran, N Homann, C Pauligk, TO Goetze, J Meiler, S Kasper, ...
The Lancet 393 (10184), 1948-1957, 2019
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink, J Schütte, ...
Jama 307 (12), 1265-1272, 2012
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
E Wardelmann, S Merkelbach-Bruse, K Pauls, N Thomas, HU Schildhaus, ...
Clinical Cancer Research 12 (6), 1743-1749, 2006
Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour
P Hohenberger, U Ronellenfitsch, O Oladeji, D Pink, P Ströbel, ...
Journal of British Surgery 97 (12), 1854-1859, 2010
Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial
H Joensuu, M Eriksson, K Sundby Hall, A Reichardt, JT Hartmann, D Pink, ...
Journal of Clinical Oncology 34 (3), 244-250, 2016
Angiotensin II directly increases transforming growth factor β1 and osteopontin and indirectly affects collagen mRNA expression in the human heart
C Kupfahl, D Pink, K Friedrich, HR Zurbrügg, M Neuss, C Warnecke, ...
Cardiovascular research 46 (3), 463-475, 2000
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature
D Pink, T Lindner, A Mrozek, A Kretzschmar, PC Thuss-Patience, ...
Gynecologic oncology 101 (3), 464-469, 2006
Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical …
H Joensuu, E Wardelmann, H Sihto, M Eriksson, KS Hall, A Reichardt, ...
JAMA oncology 3 (5), 602-609, 2017
Diffusion‐weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft‐tissue sarcomas
O Dudeck, M Zeile, D Pink, M Pech, PU Tunn, P Reichardt, WD Ludwig, ...
Journal of Magnetic Resonance Imaging: An Official Journal of the …, 2008
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study
PC Thuss-Patience, A Kretzschmar, M Repp, D Kingreen, D Hennesser, ...
Journal of Clinical Oncology 23 (3), 494-501, 2005
Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up
D Andreou, S Ruppin, S Fehlberg, D Pink, M Werner, PU Tunn
Acta orthopaedica 82 (6), 749-755, 2011
Chemotherapy in alveolar soft part sarcomas: what do we know?
P Reichardt, T Lindner, D Pink, PC Thuss-Patience, A Kretzschmar, ...
European Journal of Cancer 39 (11), 1511-1516, 2003
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
GD Demetri, PG Casali, JY Blay, M von Mehren, JA Morgan, R Bertulli, ...
Clinical Cancer Research 15 (18), 5910-5916, 2009
Substrate rigidity controls activation and durotaxis in pancreatic stellate cells
D Lachowski, E Cortes, D Pink, A Chronopoulos, SA Karim, J P. Morton, ...
Scientific reports 7 (1), 2506, 2017
Sorafenib as third-or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective …
M Montemurro, H Gelderblom, U Bitz, J Schütte, JY Blay, H Joensuu, ...
European Journal of Cancer 49 (5), 1027-1031, 2013
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA …
RD Hofheinz, GM Haag, TJ Ettrich, K Borchert, A Kretzschmar, ...
Journal of Clinical Oncology 38 (15_suppl), 4502-4502, 2020
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink, J Schütte, ...
Cancer 120 (15), 2325-2333, 2014
Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases
D Pink, D Schoeler, T Lindner, PC Thuss-Patience, A Kretzschmar, ...
Journal of Clinical Oncology 23 (27), 6809-6811, 2005
Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread—results of a large prospective trial
D Andreou, H Boldt, M Werner, C Hamann, D Pink, PU Tunn
Annals of oncology 24 (5), 1400-1405, 2013
Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib
O Dudeck, M Zeile, P Reichardt, D Pink
Annals of oncology 22 (8), 1828-1833, 2011
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20